Prostate Cancer in 2026: Risk-Adapted Treatment, Diet, Supplements and Repurposed-Drug Evidence (Integrated Guide)

Medically reviewed by Dr. Frank Yap, MD | Written by OneDayMD Editorial Team | Last updated November 2026

Quick Answer

Not every prostate cancer needs immediate treatment, but every prostate cancer needs a plan. In the ProtecT trial (1,643 men, 15-year follow-up), prostate-cancer death was low with active monitoring (3.1%), prostatectomy (2.2%) and radiotherapy (2.9%) with no significant difference, yet radical treatment roughly halved metastases (9.4% vs 4.7 to 5.0%) [1].

Match the intensity of treatment to biological risk: surveillance plus lifestyle for low-risk disease, individualized decisions for intermediate risk, and definitive standard therapy for high-risk, recurrent and metastatic disease. Exercise, weight control and a plant-forward, lower-glycemic diet are sensible foundations. No supplement, ketogenic diet or repurposed antiparasitic drug has been shown to replace or improve standard prostate-cancer treatment.

What changed in this update
  • Merged five articles (Marik's risk-adapted framework, the fenbendazole case-series summary, the diet guide, the supplement guide and the supplementary case archive) into one pillar page.
  • Added 2026 approvals: Pluvicto for PSMA-positive mHSPC (July 31) and capivasertib plus abiraterone for PTEN-deficient mHSPC (June 12); refreshed ACS 2026 statistics.
  • Added the ASCO notice, ICONIC trial status, the Hulscher Expression of Concern and Makis licensure disclosure.
  • Corrected: CAPS2 (stopped early for futility; adjusted result is post-hoc); removed an unsupported 43% diet-risk figure (UK Biobank vegetarian prostate HR was 0.69); removed curcumin 'stops metastases', aged-garlic 'stunning' claims (stomach-cancer trials, not prostate) and a leaked 'SEO Pro-Tip'; flagged vitamin E/selenium against SELECT; reclassified saw palmetto and beta-sitosterol as BPH remedies.
  • Case series: at least four patients appear to be reported more than once; entries with unconfirmed diagnoses are flagged; unverified claims about a named third party's treatment were removed.

1. Prostate cancer in 2026

The American Cancer Society estimates about 333,830 new US cases and 36,320 deaths in 2026. About 1 in 8 men is diagnosed in a lifetime and about 1 in 44 dies of it. The death rate fell by roughly half from 1993 to 2022, but incidence rose about 3% per year from 2014 to 2022, with more advanced-stage diagnoses. More than 3.5 million US men diagnosed in the past are alive today, and the average age at diagnosis is about 68 [22]. Risk is higher in Black men, for whom earlier screening discussions (from about age 45) are advised.

2. Risk-adapted framework and the ProtecT trial

The most defensible approach is neither 'treat everyone' nor 'watch everyone': treat the biology and risk of the cancer, not just the diagnosis. ProtecT randomized 1,643 men aged 50 to 69 with PSA-detected localized cancer to active monitoring, radical prostatectomy or radical radiotherapy with short-course ADT [1].

Source: Hamdy et al., NEJM 2023 [1]. CEBM Level 1b.

Outcome at median 15 years Active monitoring Prostatectomy Radiotherapy + ADT
Prostate-cancer mortality 3.1% 2.2% 2.9% (differences not significant)
Metastases 9.4% 4.7% 5.0%
Clinical progression 25.9% 10.5% 11.0%
Main harms [2,3] Deferred; accrue as men move to treatment Greatest, most persistent urinary and sexual effects More bowel effects

Five caveats when applying ProtecT to one patient

  • Mostly low-risk population: about one third had intermediate- or high-risk features by modern criteria, so results apply best to low-risk and favorable intermediate-risk disease.
  • Basic monitoring: PSA-based follow-up without routine MRI or scheduled repeat biopsy; modern MRI-based surveillance should detect progression earlier.
  • Fifteen years is not a lifetime: doubled metastases may eventually mean more deaths, especially in men with 20+ years of life expectancy.
  • Treatment has improved: enrollment was 1999 to 2009; surgery, radiotherapy and PSMA PET staging have advanced.
  • Metabolic therapy was never tested: whether lifestyle or metabolic interventions change outcomes on surveillance is unknown.

Defining biological risk

  • PSA and PSA density (above about 0.15 ng/mL per cm³ suggests more significant disease).
  • ISUP Grade Group 1 to 5, pattern-4 amount, and cribriform or intraductal histology.
  • Biopsy extent and multiparametric MRI (PI-RADS) with targeted biopsy.
  • Genomic classifiers (Decipher, Oncotype DX GPS, Prolaris) when the result could change management.
  • Germline testing with a family history of prostate, breast, ovarian or pancreatic cancer; BRCA2 carriers need a lower threshold for treatment.
  • PSMA PET for higher-risk staging; in proPSMA it was 27% more accurate than CT plus bone scan [5].

3. Four clinical pathways (with 2026 updates)

All pathway treatments above are CEBM Level 1 to 2 unless stated.

Pathway Standard approach Role of lifestyle and metabolic adjuncts Key evidence
1. Low-risk localized (Grade Group 1) Active surveillance: PSA every 3 to 6 months, MRI at entry and periodically, confirmatory biopsy within 1 to 2 years. Triggers: upgrade to GG2+ (especially GG3 or cribriform), larger tumor, new PI-RADS 4 to 5 lesion, rising PSA density or short doubling time [3,4]. Best setting for lifestyle optimization. Agree escalation criteria before starting any adjunct, and do not judge an adjunct by PSA alone. Toronto cohort (993 men): about 94% 15-year prostate-cancer-specific survival [11]. In ProtecT about 24% of monitored men never needed radical treatment [1].
2. Intermediate-risk (the decision zone) Favorable (small GG2, low volume, low PSA density, no cribriform): surveillance reasonable. Unfavorable: prostatectomy, or radiotherapy with 4 to 6 months of ADT [3]. Continue lifestyle measures in either branch; never use them to delay curative treatment when biology worsens. Decisions weigh life expectancy, baseline urinary and sexual function and patient values.
3. High-risk localized Radiotherapy with 18 to 36 months of ADT (± abiraterone), or prostatectomy with pelvic node dissection in selected men; salvage radiotherapy when PSA rises [3,4]. Lifestyle counters ADT effects on weight, insulin resistance, muscle and heart. Check interactions with abiraterone, enzalutamide and apalutamide. STAMPEDE: adding abiraterone raised 6-year survival from 77% to 86% in very-high-risk disease [13]. Early salvage RT matched adjuvant RT (5-year event-free 88% vs 89%) [14].
4. Recurrent or metastatic High-risk biochemical recurrence (PSA doubling time 9 months or less): enzalutamide + leuprolide [15]. Oligometastatic: SBRT [16]. mHSPC: ADT + androgen receptor pathway inhibitor ± docetaxel ± prostate radiotherapy [17]. Germline and tumor testing for all metastatic disease [3]. Supportive and investigational only: protect muscle, bone and cardiometabolic health during long-term hormonal therapy; screen every adjunct for interactions. EMBARK: 8-year survival 78.9% vs 69.5% [15]. VISION (Lu-PSMA, mCRPC) [19]; olaparib for BRCA/HRR alterations [18].
2026 updates in metastatic disease
  • July 31, 2026: FDA approved Pluvicto (lutetium-177 vipivotide tetraxetan) with an ARPI for PSMA-positive metastatic hormone-sensitive disease. PSMAddition: progression or death HR 0.72 initially and 0.67 on updated analysis; overall survival trend HR 0.80 (95% CI 0.63 to 1.01), not yet statistically significant [20].
  • June 12, 2026: FDA approved capivasertib plus abiraterone and prednisone for PTEN-deficient metastatic hormone-sensitive disease (CAPItello-281, improved radiographic progression-free survival), with a companion PTEN assay [21].

4. Metabolic foundation: exercise, weight and diet

Improving metabolic health is a sensible foundation at every stage, but the evidence is suggestive rather than definitive.

Intervention What was found How to read it Tier
Exercise Health Professionals Follow-up Study: 3+ hours per week of vigorous activity after diagnosis was linked to 61% lower prostate-cancer death than under 1 hour [6]. Observational; also reduces fatigue and preserves muscle during ADT. CEBM 3
Low-carbohydrate diet (CAPS2) 57 men with rising PSA were randomized for 6 months; the trial stopped early for futility with 45 completers. Weight and metabolic markers improved; the primary PSA-doubling-time outcome was not significantly different. A post-hoc adjusted analysis showed 28 vs 13 months [7]. Hypothesis-generating only; the adjusted result was not pre-specified and cannot separate carbohydrate restriction from weight loss. CEBM 2
Vegetable-focused diet (MEAL) 478 men on surveillance greatly increased vegetables with no reduction in progression at 2 years [8]. Generic advice is not enough; specific, sustained and tested strategies are needed. CEBM 2
Metabolic harm of ADT; metformin ADT raises fat mass, insulin resistance, diabetes and cardiovascular risk [9]. In STAMPEDE, metformin did not improve survival but cut weight gain (2.0 vs 4.4 kg over 2 years) [10]. Metabolic care is justified on cardiometabolic grounds alone during ADT. CEBM 1b to 2

A ketogenic diet is a reasonable option for motivated men if protein intake and muscle mass are protected, particularly in older men and those on ADT. It is a complement to treatment, not a replacement for surgery, radiotherapy or systemic therapy when indicated.

5. Foods to add and limit

No food is a treatment. These patterns support general, cardiovascular and metabolic health during and after prostate-cancer care.

Food or pattern What the evidence shows Practical note Tier
Cooked tomatoes (lycopene) Observational studies and meta-analyses link higher intake to lower risk; supplement trials are inconsistent. Cook with olive oil; lycopene is fat-soluble. CEBM 3
Cruciferous vegetables (sulforaphane) Laboratory and small-trial signals only (see supplements). Aim for 3 to 5 servings per week. CEBM 2 to 3
Green tea (EGCG) Observational and small-trial data; laboratory growth inhibition. Brewed tea is the low-risk route; high-dose extracts can harm the liver. CEBM 3
Fatty fish, walnuts, flax and chia (omega-3) A 1-year trial of a high omega-3, low omega-6 diet with fish oil lowered Ki-67 in prostate tissue [25]. Surrogate biomarker, not survival. CEBM 2
Plant-forward, vegetarian or fish-based patterns UK Biobank men: vegetarians HR 0.69 (95% CI 0.54 to 0.89) and fish-eaters HR 0.80 (0.65 to 0.99) for prostate-cancer incidence; authors note residual confounding or detection differences. A second analysis found no robust prostate association in a meta-analysis [24]. The earlier 'up to 43% lower risk' figure was not supported and is removed. CEBM 3
Red and processed meat; charred meat Links to advanced prostate cancer are inconsistent; heterocyclic amines from charring are experimentally carcinogenic. Processed meat is clearly linked to colorectal cancer. Limit processed meat; avoid charring. CEBM 3
Very high dairy or calcium Some cohorts link very high intake to more advanced disease; results are mixed. On ADT, bone protection still matters: aim for about 1,000 to 1,200 mg calcium per day from diet and supplements combined, plus adequate vitamin D. CEBM 3
Refined sugar, trans fat, excess weight Obesity is associated with more aggressive disease and worse ADT side effects. Weight and glucose control are the main levers. CEBM 3

6. Supplements ranked by evidence

The earlier 'Top 10 Prostate Cancer Fighting Supplements' list is re-ranked here by the strength of prostate-specific evidence. Doses are the ranges used in the earlier article, not prescriptions; discuss every supplement with your oncologist.

Rank Supplement (range cited) Prostate-specific evidence Cautions Tier
1 Omega-3 EPA+DHA (1,000 to 2,000 mg/day) CAPFISH-3 RCT: high omega-3 diet with fish oil for 1 year lowered Ki-67 in men on surveillance [25]. Observational data on blood omega-3 and high-grade risk are mixed. Bleeding risk with anticoagulants. CEBM 2
2 Vitamin D3 (1,000 to 4,000 IU/day) Small pre-prostatectomy trial (4,000 IU for 60 days) showed less aggressive tumors. Large general-population trials did not reduce overall cancer incidence. Check 25-OH vitamin D first; excess causes hypercalcemia. CEBM 2 to 3
3 Sulforaphane (broccoli extract) 78 men with rising PSA after prostatectomy: primary endpoint missed; PSA doubling time 28.9 vs 15.5 months [12]. Small, single trial. CEBM 2
4 Green tea extract / EGCG (200 to 400 mg/day) (affiliate link) Observational risk reduction and slowed progression in early-stage studies; a 500 mg 70% EGCG capsule equals roughly 5 to 7 cups of tea. High-dose extracts can cause liver toxicity. CEBM 3
5 Lycopene (10 to 30 mg/day) Tomato-product intake is linked to lower risk; supplement trials are inconsistent. Food first. CEBM 3
6 Curcumin (500 to 1,000 mg/day) (affiliate link) Laboratory anti-inflammatory and anti-proliferative effects; no clinical evidence that it prevents metastasis (earlier claim removed). Additive blood-thinning effect; digestive upset. CEBM 4 to 5
7 Zinc (15 to 30 mg/day) Important for prostate cell function; supplement-risk associations are conflicting. Stay under the 40 mg/day adult upper limit; excess lowers copper. CEBM 3
8 Aged garlic extract Large garlic trials were in stomach cancer, not prostate. Claims of 'stunning' protection and NK-cell increases of 300% are removed pending prostate data. No prostate-specific trials. CEBM 5 for prostate
9 Saw palmetto (160 mg twice daily) and beta-sitosterol (60 to 130 mg/day) Studied for urinary symptoms of benign prostatic enlargement (BPH), not cancer treatment. Not anticancer therapies; may interact with hormonal drugs. BPH only
10 Avoid: vitamin E and selenium supplements SELECT (35,000 men): no prevention benefit, and vitamin E increased prostate-cancer risk [23]. The earlier 'works synergistically with vitamin E' statement is removed. Obtain selenium from food (adult RDA 55 mcg). CEBM 1 (negative)

7. Repurposed antiparasitic drugs: what the evidence shows

Ivermectin, fenbendazole and mebendazole show anticancer activity in laboratory and animal studies, but no randomized trial has shown a benefit in prostate cancer or any other cancer. The University of Florida ICONIC trial (NCT07487805; phase 2, 80 patients, ivermectin plus checkpoint inhibitors) was listed as not yet recruiting when last verified in October 2026, with an immune-cell biomarker as its primary outcome [27].

The Hulscher et al. 2026 cohort

A telemedicine-recruited survey of 197 patients on 25 mg ivermectin plus 250 mg mebendazole capsules (up to 4 per day) included 55 men with prostate cancer; 122 patients completed follow-up. Self-reported 'clinical benefit' was 84.4%, with 32.8% reporting no evidence of disease [28]. The Anticancer Research Expression of Concern, self-reported outcomes, absent controls and concurrent conventional treatment mean it cannot show that the drugs worked.

Audit of the prostate case-report compilation (135 entries, 2022 to 2026)

  • ADT confounding: an analysis of the series estimated that 70 to 80% of patients were receiving standard hormone therapy at the same time [30].
  • Duplicates: at least four patients appear more than once (Connecticut man: Cases 65, 67 and 128; Texas man: Cases 39 and 58; California man: Cases 48 and 130; Australian man: Cases 36 and 46, a probable match). The true number of distinct patients is lower than 135, and the 55-patient Hulscher block is a survey, not 55 case reports.
  • Unconfirmed diagnoses: Cases 55 and 133 describe MRI lesions without a biopsy-confirmed starting diagnosis.
  • Misleading endpoints: a drop in Gleason score between biopsy and prostatectomy or repeat biopsy (Cases 26 and 40) is common from sampling variability alone.
  • Non-responders exist: Case 64's PSA kept rising on self-directed ivermectin and fenbendazole before chemoradiation was added; the compiler also acknowledges non-responders.

Selected, distinct patients. Source: the supplementary prostate case archive and the Substack compilation [29,30].

Case(s) Patient Concurrent conventional treatment Reported repurposed regimen Reported outcome Tier
132 49M, Stage 4, Illinois ADT, darolutamide, docetaxel, SBRT Ivermectin, fenbendazole, MCP, CBD PSA 127 to 0.44 at 6 months; PET burden decreased CEBM 4 (confounded)
48, 130 63M, Stage 4 Gleason 9, California Lupron, abiraterone, docetaxel (6 cycles) Ivermectin, fenbendazole, CBD PSA 44 to 0.17 at 3 months; later below 0.01 CEBM 4 (confounded)
65, 67, 128 53M, Stage 4 bone, Connecticut Hormone therapy (oncologist unaware of regimen) Ivermectin, fenbendazole PSA 948 to about 1.1 to 1.4 at 6 months; PSMA PET 50% less disease CEBM 4 (confounded)
54 68M, Stage 4 Gleason 9, Virginia Orgovyx, abiraterone Ivermectin, fenbendazole, CBD Complete response at 6 months CEBM 4 (confounded)
127 66M, Stage 4 bone, Texas Radiation to spine (5 fractions) Ivermectin, fenbendazole Improved bone metastases at 8 months CEBM 4 (confounded)
39, 58 66M, extensive bone metastases, Texas Not stated Ivermectin, fenbendazole (dose escalated) PSA 531 to 0.19; bone healing reported CEBM 4 to 5
135 56M, Gleason 7 (4+3), Ohio None reported Ivermectin, fenbendazole, MCP, CBD PSA 15.35 to 10.88 at 4 months; no imaging CEBM 5
125 56M, early stage, Gleason 7, UK Declined treatment; IV mistletoe also used Ivermectin, fenbendazole PSA 11.8 to 3.6 at 3 months; returned to surveillance CEBM 5
133, 55 71M and 60s M, MRI lesions None reported Ivermectin, fenbendazole Lesion 'resolved' on MRI or biopsy; initial cancer diagnosis not confirmed CEBM 5
26, 40 61M and 61M, Gleason 7 to 8 Prostatectomy (Case 26) Ivermectin, fenbendazole Gleason score lower on later pathology or biopsy CEBM 5 (sampling variability)
64 Stage 4 with bone and nodal metastases Concurrent chemoradiation (second phase) Ivermectin, fenbendazole, mebendazole PSA rose on self-directed regimen; response only after chemoradiation added CEBM 5

Reported regimens (descriptive, not recommendations): case reports describe ivermectin from about 12 to 60+ mg/day (or 1 to 1.5 mg/kg/day), fenbendazole from 222 to 2,000 mg/day and mebendazole 250 to 1,000 mg/day, often with modified citrus pectin, CBD, curcumin or a ketogenic diet. Claims that higher fenbendazole doses are needed come from uncontrolled reports; doses at the top of these ranges have no human cancer-trial validation.

Bottom line

The reported responses are hypothesis-generating at best. The pattern of concurrent hormone therapy, duplicates and unconfirmed diagnoses means these reports cannot separate any effect of the antiparasitics from standard treatment. Randomized trials with molecular profiling (AR-V7, HRR genes, PTEN), defined denominators and blinded imaging review are required.

8. Safety and interactions

Issue Why it matters
Liver Transient AST/ALT elevations are reported with fenbendazole and mebendazole; abiraterone can also cause liver toxicity. Monitor liver tests if any adjunct is used.
Neurotoxicity High-dose ivermectin can cause neurologic toxicity; transient visual symptoms are reported above about 60 mg/day. The ICONIC protocol itself cites a severe neurotoxicity case in a patient also taking regorafenib.
Drug interactions Ivermectin and fenbendazole share CYP3A4 and P-glycoprotein pathways with many cancer drugs. Enzalutamide and apalutamide are strong enzyme inducers that can lower levels of co-administered drugs.
Delayed or displaced treatment The main risk is substituting an unproven regimen for treatment that works, particularly in intermediate- and high-risk disease.
Supplements Vitamin E and selenium (no benefit, possible harm); high-dose green tea extract (liver); zinc above 40 mg/day; fish oil with anticoagulants.

9. Evidence summary (CEBM tiers)

Scale: Level 1 = randomized trials or systematic reviews; Level 2 = lower-quality or surrogate-outcome RCTs and cohort studies; Level 3 = observational or case-control; Level 4 = case series; Level 5 = mechanistic, preclinical or expert opinion.

Intervention Tier Status
Active surveillance for low-risk disease 1b to 2 Standard of care
Radical treatment vs monitoring (ProtecT) 1b Reduces metastases; no 15-year survival difference
ADT + ARPI, abiraterone, docetaxel, salvage RT, PARP inhibitors, Lu-PSMA, capivasertib 1 Standard of care for the stated indications
Exercise 3 Recommended for health and ADT side effects
Low-carbohydrate / ketogenic diet 2 Weight and metabolic benefit; no proven anticancer effect
Omega-3 diet with fish oil; sulforaphane 2 Surrogate or negative-primary results
Vitamin E and selenium supplements 1 (negative) Not recommended
EGCG, lycopene, vitamin D, zinc 2 to 3 Mixed; food first
Curcumin, saw palmetto, beta-sitosterol, aged garlic 4 to 5 Not established for prostate cancer
Ivermectin, fenbendazole, mebendazole 4 to 5 Not recommended outside trials (ASCO 2026)

10. Action checklist

  • Ask for your Grade Group, PSA density, MRI (PI-RADS) result and whether genomic or germline testing could change your plan.
  • Take time: most localized cancers allow weeks for a second opinion; avoid rushed decisions.
  • Agree escalation triggers (MRI, biopsy, PSA kinetics) before starting any adjunct.
  • Tell your oncologist about every supplement and drug, including veterinary or compounded products; ask about interactions and liver monitoring.
  • Build exercise (aerobic plus resistance) and weight control into your plan, especially on ADT.
  • Ask about clinical trials; that is the safe route to experimental therapy.

11. FAQ

Does every prostate cancer need immediate treatment?

No. In the ProtecT trial of 1,643 men, 15-year prostate-cancer mortality was low with active monitoring (3.1%), prostatectomy (2.2%) and radiotherapy (2.9%), with no significant difference. Radical treatment did roughly halve metastases (about 5% vs 9.4%). Low-risk cancers are often managed with surveillance; higher-risk cancers generally need definitive treatment.

Can diet or supplements treat prostate cancer?

No diet or supplement has been shown to replace surgery, radiotherapy or hormone-based therapy. Exercise, weight control and a plant-forward diet are reasonable foundations with cardiometabolic benefits. Vitamin E and selenium supplements did not prevent prostate cancer in the SELECT trial, and vitamin E increased risk.

Are ivermectin, fenbendazole or mebendazole proven to treat prostate cancer?

Evidence consists of laboratory studies, uncontrolled case reports and a self-reported telemedicine survey. The only registered US ivermectin trial found (ICONIC, NCT07487805) was listed as not yet recruiting in October 2026.

Why do some case reports show large PSA drops?

Most reported patients were also receiving hormone therapy, chemotherapy, radiation or other standard treatment, which can lower PSA dramatically. The reports also lack denominators, central imaging review and failures, and some patients appear to be reported more than once.

Which prostate supplements should be avoided?

High-dose vitamin E and selenium supplements are not recommended for prostate-cancer prevention based on SELECT. Zinc should stay within the 40 mg/day adult upper limit. Saw palmetto and beta-sitosterol are studied for urinary symptoms of benign enlargement, not as cancer treatments. Always tell your oncologist about every supplement.

What is new for metastatic prostate cancer in 2026?

The FDA approved lutetium-177 PSMA-617 (Pluvicto) with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive disease on July 31, 2026, and capivasertib plus abiraterone for PTEN-deficient metastatic hormone-sensitive disease on June 12, 2026.

Is a ketogenic diet safe during hormone therapy?

A low-carbohydrate or ketogenic diet can cause weight loss and metabolic improvement, but it has not been shown to slow prostate cancer in a randomized trial with a positive primary result. Men on androgen deprivation therapy need enough protein and resistance exercise to protect muscle, so plan it with an oncologist or dietitian.

12. References

  1. Hamdy FC et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547-1558.
  2. Donovan JL et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy. N Engl J Med. 2016;375:1425-1437.
  3. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (current version).
  4. Cornford P et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer, 2024 update. Eur Urol. 2024;86:148-163.
  5. Hofman MS et al. PSMA PET-CT in high-risk prostate cancer (proPSMA). Lancet. 2020;395:1208-1216.
  6. Kenfield SA et al. Physical activity and survival after prostate cancer diagnosis. J Clin Oncol. 2011;29:726-732.
  7. Freedland SJ et al. CAPS2 randomized trial. Clin Cancer Res. 2020;26:3035-3043. doi
  8. Parsons JK et al. MEAL randomized clinical trial. JAMA. 2020;323:140-148.
  9. Keating NL et al. Diabetes and cardiovascular disease during ADT. J Clin Oncol. 2006;24:4448-4456.
  10. Gillessen S et al. Metformin with ADT in metastatic prostate cancer (STAMPEDE). Lancet Oncol. 2025.
  11. Klotz L et al. Long-term follow-up of a large active surveillance cohort. J Clin Oncol. 2015;33:272-277.
  12. Cipolla BG et al. Sulforaphane in men with biochemical recurrence. Cancer Prev Res. 2015;8:712-719.
  13. Attard G et al. Abiraterone with or without enzalutamide, high-risk non-metastatic disease (STAMPEDE). Lancet. 2022;399:447-460.
  14. Vale CL et al. Adjuvant or early salvage radiotherapy (ARTISTIC). Lancet. 2020;396:1422-1431.
  15. Freedland SJ et al. Enzalutamide in biochemically recurrent prostate cancer (EMBARK). N Engl J Med. 2025.
  16. Ost P et al. STOMP. J Clin Oncol. 2018;36:446-453; Phillips R et al. ORIOLE. JAMA Oncol. 2020;6:650-659.
  17. Parker CC et al. Radiotherapy to the primary tumour in metastatic disease (STAMPEDE). Lancet. 2018;392:2353-2366.
  18. de Bono J et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
  19. Sartor O et al. Lutetium-177-PSMA-617 for mCRPC (VISION). N Engl J Med. 2021;385:1091-1103.
  20. FDA approval of Pluvicto for PSMA-positive mHSPC, July 31, 2026 (Novartis release). link
  21. FDA approval of capivasertib with abiraterone for PTEN-deficient mHSPC, June 12, 2026. FDA
  22. American Cancer Society. Key Statistics for Prostate Cancer, 2026. link
  23. Klein EA et al. Vitamin E and the risk of prostate cancer: SELECT. JAMA. 2011;306:1549-1556.
  24. Parra-Soto S et al. BMC Med. 2022 doi; Watling CZ et al. BMC Med. 2022 doi
  25. CAPFISH-3 randomized trial, J Clin Oncol. 2024. abstract
  26. ASCO Clinical Notice: recommending against ivermectin and fenbendazole for cancer treatment outside clinical trials (2026). ASCO
  27. ClinicalTrials.gov NCT07487805 (ICONIC), status verified October 2026. record
  28. Hulscher N et al. 2026 ivermectin-mebendazole cohort. summary
  29. Marik P. Prostate Cancer: When Less Treatment May Be More. Substack, Oct 11, 2026. link
  30. Fenbendazole & Cancer. Key Findings on Prostate Cancer from Repurposed Antiparasitic Protocols. Oct 1, 2026. link
Medical and affiliate disclaimer

This article is educational and not medical advice. Do not start, stop or change prostate-cancer treatment, supplements or off-label drugs without a licensed clinician who knows your history. Ivermectin is FDA-approved only for specific parasitic infections, and fenbendazole is a veterinary drug not approved for humans. Affiliate disclosure: OneDayMD may earn a commission from the Amazon Associates and The Wellness Company links marked above at no extra cost to you.

Related: All prostate cancer articles | Full case-series compilation (all cancers)

Ask OneDayMD AI

Explore this topic with AI

Ask our research assistant questions about this article, related clinical studies, medical evidence and other OneDayMD resources.

Explore with OneDayMD AI

Powered by Google Gemini Notebook · Curated OneDayMD research sources

Comments

Popular posts from this blog

Top 20 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Ivermectin for Cancer: Dr. William Makis Protocol and Others Explained (2026 Guide)

Dr. William Makis's Recommended Ivermectin, Fenbendazole and Mebendazole Dosages for Cancer (2026)

Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective

Ivermectin & Fenbendazole for Lung Cancer: 63 Cases Analyzed (2026)

Ivermectin Dosage for Cancer in 2026: Marik vs Makis vs Hope — What the Numbers Actually Are

Cancer Prevention Supplements & Diet: The I-PREVENT + ROOT Protocol (2026)

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

Archive

Show more